[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100469045":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":26,"locations":32,"responsibleParty":49,"collaborators":11,"id":51,"slug":11,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":11,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":11,"overallStatus":69,"whyStopped":11,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Assistance Publique Hopitaux De Marseille","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Knee prosthesis group","EXPERIMENTAL",null,[13],"Other: Thrombotic risk assessment",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":11},"Thrombotic risk assessment","Collection of symptomatic thrombotic events occurring during the 5 days of hospitalization and then by telephone interview at M1 +\u002F- 3 days. Complete echodoppler (proximal and distal) performed at M1 to highlight asymptomatic thrombotic events.",[9],[20,23],{"name":21,"affiliation":5,"role":22},"François CREMIEUX","STUDY_DIRECTOR",{"name":24,"affiliation":5,"role":25},"Matthieu OLLIVIER","PRINCIPAL_INVESTIGATOR",[27],{"name":24,"role":28,"phone":29,"phoneExt":30,"email":31},"CONTACT","04.91.74.50.12","+33","matthieu.ollivier@ap-hm.fr",[33],{"facility":34,"status":11,"city":35,"state":36,"zip":37,"country":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Assistance Publique Hopitaux de Marseille","Marseille","Bouches Du Rhône","13354","France",{"type":40,"coordinates":41},"Point",[42,43],5.38107,43.29695,{"lat":43,"lon":42},[46],{"name":47,"role":28,"phone":11,"phoneExt":11,"email":48},"Alexandra GIULIANI","alexandra.giuliani@ap-hm.fr",{"type":50,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100469045",false,"NCT05387694","Study of the Prognostic Value of the Coagulolytic Balance Dependent on Circulating Microvesicles in the Occurrence of Thrombotic Events After Total Knee Replacement in Orthopedic Surgery.","MOTiVE","Inclusion Criteria:\n\n* Subject, male or female, aged 18 to 85 years (upper age limit classically used in the literature of PTG79-81)\n* First-line TKP (knee native to any prosthesis) performed to treat primary or secondary osteoarthritis.\n\nIn case of contralateral PTG, a delay of 12 months between the 2 prostheses will be respected according to the habits of the inclusion centers.\n\n* ASA score \\\u003C4 (American Society of Anesthesiologists)\n* No contraindication to prophylactic treatment with low molecular weight heparin (LMWH)\n* Subject not taking anticoagulant or antiaggregant therapy at therapeutic dose\n* Subject who has signed the informed consent form\n* Subject affiliated to the social security system\n\nExclusion Criteria:\n\n* Subjects with a history of sepsis, tumor or trauma in the considered joint\n* Subject with sepsis or acute infection\n* Immunocompromised subject (HIV, transplant, chemotherapy, leukemia, glucocorticoids \\>3 months)\n* Subjects with severe respiratory, circulatory or cardiac pathologies involving anticoagulant treatment likely to influence the coagulolytic balance.\n* Subject with severe renal insufficiency (creatinine clearance \\\u003C 30ml\u002Fmin)\n* Subject refusing to participate in the study or not signing the informed consent or unable to adhere to the study procedures\n* Subjects who are minors, pregnant or breastfeeding, not affiliated with the social security system, or deprived of liberty\n* Subject already included in an interventional trial (which may alter the results of that study)","ALL","18 Years","85 Years",{"count":61,"type":62},387,"ESTIMATED","INTERVENTIONAL",[65],"NA","This is a prospective multicenter cohort study to evaluate the prognostic value of new biological markers in predicting thrombotic events after orthopedic surgery. According to the inclusion and non-inclusion criteria below, the study will include 387 major subjects who will undergo first-line total knee replacement and will receive the same standard prophylactic treatment: anticoagulation with Lovenox® (enoxaparin) 4000 IU\u002Fd subcutaneously 6 to 8 hours postoperatively and then daily for 15 days in combination with compression stockings.",[68],"Knee Prosthesis","NOT_YET_RECRUITING","2023-04-20",{"date":72,"type":73},"2023-04-21","ACTUAL",{"date":75,"type":62},"2023-06",{"date":77,"type":62},"2026-12",{"name":5,"class":6},1]